Furthermore, in patients with completely resected early-stage NSCLC harboring mutated EGFR, adjuvant EGFR-TKI therapy may significantly prolong disease free survival as an important treatment option [82]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.